Hong Ku Ha1, Phillip J Koo2, Seong-Jang Kim3,4,5. 1. Department of Urology, Pusan National University Hospital, Busan, Republic of Korea. 2. Diagnostic Imaging, Banner MD Anderson Cancer Center, Gilbert, Arizona, USA. 3. Department of Nuclear Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea. 4. BioMedical Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea. 5. Department of Nuclear Medicine, School of Medicine, Pusan National University, Busan, Republic of Korea.
Abstract
AIMS: We aimed to assess the diagnostic accuracy of F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for preoperative lymph node (LN) staging in newly diagnosed bladder cancer (BC) patients through a systematic review and meta-analysis. PATIENTS AND METHODS: MEDLINE, Embase, and the Cochrane Library database, from the earliest available date of indexing through June 30, 2017, were searched for studies evaluating the diagnostic performance of F-18 FDG PET/CT for preoperative LN staging in newly diagnosed BC. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves. RESULTS: Across 14 studies (785 patients), the pooled sensitivity was 0.57 (95% CI: 0.49-0.64) and the pooled specificity was 0.92 (95% CI: 0.87-0.95). The LR syntheses gave an overall LR+ of 7.4 (95% CI: 4.4-12.3) and an LR- of 0.47 (95% CI: 0.39-0.56). The pooled diagnostic odds ratio was 16 (95% CI: 9-28). CONCLUSIONS: F-18 FDG PET/CT shows a low sensitivity and high specificity for the detection of metastatic LNs in patients with newly diagnosed BC.
AIMS: We aimed to assess the diagnostic accuracy of F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for preoperative lymph node (LN) staging in newly diagnosed bladder cancer (BC) patients through a systematic review and meta-analysis. PATIENTS AND METHODS: MEDLINE, Embase, and the Cochrane Library database, from the earliest available date of indexing through June 30, 2017, were searched for studies evaluating the diagnostic performance of F-18FDG PET/CT for preoperative LN staging in newly diagnosed BC. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves. RESULTS: Across 14 studies (785 patients), the pooled sensitivity was 0.57 (95% CI: 0.49-0.64) and the pooled specificity was 0.92 (95% CI: 0.87-0.95). The LR syntheses gave an overall LR+ of 7.4 (95% CI: 4.4-12.3) and an LR- of 0.47 (95% CI: 0.39-0.56). The pooled diagnostic odds ratio was 16 (95% CI: 9-28). CONCLUSIONS:F-18FDG PET/CT shows a low sensitivity and high specificity for the detection of metastatic LNs in patients with newly diagnosed BC.
Authors: Avinash Maganty; Robert M Turner; Jonathan G Yabes; Dwight E Heron; Jeffrey R Gingrich; Benjamin J Davies; Bruce L Jacobs Journal: Eur J Cancer Care (Engl) Date: 2020-02-05 Impact factor: 2.520
Authors: Michał Frączek; Hubert Kamecki; Anna Kamecka; Roman Sosnowski; Katarzyna Sklinda; Marcin Czarniecki; Leszek Królicki; Jerzy Walecki Journal: Transl Androl Urol Date: 2018-10
Authors: Vincenzo Cuccurullo; Giuseppe Danilo Di Stasio; Francesco Manti; Pierpaolo Arcuri; Rocco Damiano; Giuseppe Lucio Cascini Journal: Diagnostics (Basel) Date: 2021-05-11
Authors: Xiaopan Xu; Huanjun Wang; Yan Guo; Xi Zhang; Baojuan Li; Peng Du; Yang Liu; Hongbing Lu Journal: Front Oncol Date: 2021-07-15 Impact factor: 6.244
Authors: Antonio Gómez Caamaño; Ana M García Vicente; Pablo Maroto; Alfredo Rodríguez Antolín; Julián Sanz; María Almudena Vera González; Miguel Ángel Climent Journal: Curr Oncol Date: 2021-12-03 Impact factor: 3.677